title: Quantitative analysis of tumor shrinkage due to chemotherapy and its implication for radiation treatment planning in limited-stage small-cell lung cancer.
abstract: BACKGROUND
  The optimal timing of chemoradiotherapy in limited-stage small-cell lung cancer (LS-SCLC) hasn't been established, although evidence from studies supported that patients can benefit from early radiation therapy. The purpose of this study was to quantify tumor shrinkage in response to induction chemotherapy (IC), evaluate the impact of tumor shrinkage on radiation dosimetric parameters and determine its implication for the timing of radiation therapy for patients with LS-SCLC.
  
  
  METHODS
  Twenty patients with LS-SCLC who were treated with IC followed by concomitant radiation therapy were investigated retrospectively. Ten patients received 1 cycle of IC, and 10 patients received 2 cycles of IC. Pre-IC CT imaging was coregistered with a simulation CT, and virtual radiation plans were created for pre- and post-IC thoracic disease in each case. The changes in the gross target volume (GTV), planning target volume (PTV) and dosimetric factors associated with the lungs, esophagus and heart were analyzed.
  
  
  RESULTS
  The mean GTV and PTV for all of the patients decreased by 60.9% and 40.2%, respectively, which resulted in a significant reduction in the radiation exposure to the lungs, esophagus and heart. Changes in the PTV and radiation exposure of normal tissue were not significantly affected by the number of chemotherapy cycles delivered, although patients who received 2 cycles of IC had a greater decrease in GTV than those who received only 1 cycle of IC (69.6% vs. 52.1%, p = 0.273).
  
  
  CONCLUSIONS
  Our data showed that targeting the tumor post-IC may reduce the radiation dose to normal tissue in patients with LS-SCLC. However, the benefit to the normal tissue was not increased by an additional cycle of IC. These findings suggest that the first cycle of chemotherapy is very important for tumor shrinkage and that initiating thoracic radiation therapy at the second cycle of chemotherapy may be a reasonable strategy for timing of radiation therapy in LS-SCLC treatment.
authors.affiliation: Department of Radiation Oncology, Shanghai Cancer Center, Fudan University, 270 Dong An Road, Shanghai 200032, China. xlfu1964@hotmail.com.
authors.forename: Bing
authors.initials: B
authors.lastname: Xia
authors.forename: Jia-Zhou
authors.initials: JZ
authors.lastname: Wang
authors.forename: Qi
authors.initials: Q
authors.lastname: Liu
authors.forename: Jing-Yi
authors.initials: JY
authors.lastname: Cheng
authors.forename: Zheng-Fei
authors.initials: ZF
authors.lastname: Zhu
authors.forename: Xiao-Long
authors.initials: XL
authors.lastname: Fu
mesh_terms: D000368:Aged; D059248:Chemoradiotherapy / Q000379:methods*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy; D008297:Male; D008875:Middle Aged; D011829:Radiation Dosage; D011874:Radiometry; D011880:Radiotherapy Planning, Computer-Assisted / Q000379:methods*; D012189:Retrospective Studies; D055752:Small Cell Lung Carcinoma / Q000188:drug therapy / Q000473:pathology* / Q000532:radiotherapy
references.citation: Radiother Oncol. 2012 Feb;102(2):258-62
references.pmid: 22056536
references.citation: Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):e91-7
references.pmid: 21489716
references.citation: N Engl J Med. 1999 Jan 28;340(4):265-71
references.pmid: 9920950
references.citation: Radiother Oncol. 2006 Sep;80(3):307-12
references.pmid: 16949169
references.citation: Int J Radiat Oncol Biol Phys. 2004 Jul 15;59(4):943-51
references.pmid: 15234027
references.citation: Cancer. 2012 Jan 1;118(1):278-87
references.pmid: 21598237
references.citation: Int J Radiat Oncol Biol Phys. 2008 Oct 1;72(2):327-34
references.pmid: 18793952
references.citation: J Clin Oncol. 2006 Aug 20;24(24):3823-30
references.pmid: 16921033
references.citation: J Clin Oncol. 1987 Apr;5(4):592-600
references.pmid: 3031226
references.citation: J Clin Oncol. 2006 Mar 1;24(7):1057-63
references.pmid: 16505424
references.citation: J Clin Oncol. 1997 Mar;15(3):893-900
references.pmid: 9060525
references.citation: Radiother Oncol. 2007 May;83(2):203-13
references.pmid: 17482301
references.citation: Cancer Treat Rev. 2007 Aug;33(5):461-73
references.pmid: 17513057
references.citation: Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):329-36
references.pmid: 19782478
references.citation: J Clin Oncol. 1993 Feb;11(2):336-44
references.pmid: 8381164
references.citation: Ann Oncol. 2006 Apr;17(4):543-52
references.pmid: 16344277
references.citation: Lancet. 2011 Nov 12;378(9804):1741-55
references.pmid: 21565397
references.citation: Int J Radiat Oncol Biol Phys. 2012 Jul 15;83(4):e531-6
references.pmid: 22560543
references.citation: J Thorac Oncol. 2007 Jul;2(7):645-51
references.pmid: 17607121
references.citation: Radiother Oncol. 2008 Apr;87(1):49-54
references.pmid: 18342967
references.citation: Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):993-1000
references.pmid: 17869016
references.citation: Ann Oncol. 2001 Sep;12(9):1231-8
references.pmid: 11697833
references.citation: Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):998-1003
references.pmid: 21353159
references.citation: Br J Cancer. 2006 Mar 13;94(5):625-30
references.pmid: 16465191
references.citation: J Thorac Oncol. 2009 Apr;4(4):527-33
references.pmid: 19240650